Figure 4.
Effect of EGCG on proliferation of myeloma cells in vivo. CB-17 SCID mice were inoculated subcutaneously in the interscapular area with 5 × 106 OPM1 myeloma cells. Following appearance of tumors, the mice were treated intraperitoneally with PBS alone or EGCG 33 mg/kg/d. When mice were humanely killed, tumors were excised and analyzed for apoptosis by flow cytometry. (A) Cell-cycle profiles of tumor cells derived from control and EGCG-treated mice. (B) Survival curve of control and EGCG-treated mice.
